Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2601)
All Articles published online
|
Sep 21, 2009 (publication date) through Apr 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Huang WS, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol 2009; 15(35): 4464-4466 [PMID: 19764104 DOI: 10.3748/wjg.15.4464] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i35/4464.htm |
| Number | Citing Articles |
| 1 |
Satoru Joshita, Kaname Yoshizawa, Kenji Sano, Satoshi Kobayashi, Tomohiro Sekiguchi, Susumu Morita, Atsushi Kamijo, Michiharu Komatsu, Takeji Umemura, Tetsuya Ichijo, Akihiro Matsumoto, Eiji Tanaka. A Patient with Advanced Hepatocellular Carcinoma Treated with Sorafenib Tosylate Showed Massive Tumor Lysis with Avoidance of Tumor Lysis syndrome. Internal Medicine 2010; 49(11): 991 doi: 10.2169/internalmedicine.49.3153
|
| 2 |
Yadong Wang, Tiange Wang, Jianchao Xue, Ziqi Jia, Xinyu Liu, Bowen Li, Ji Li, Xiaoguang Li, Weiwei Wang, Zhongxing Bing, Lei Cao, Zhili Cao, Naixin Liang. Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.809467
|
| 3 |
Chieko Kudo, Masahito Miura, Makio Gamoh, Tomohito Niitani, Hiroki Tamagawa, Kiichi Takahashi, Sonoko Ichikawa, Katsuo Sugiyama. Tumor lysis syndrome after treatment with sorafenib for hepatocellular carcinoma. International Cancer Conference Journal 2015; 4(3): 147 doi: 10.1007/s13691-014-0186-2
|
| 4 |
Sardar Zakariya Imam, Mohammad Faizan Zahid, Muhammad Asad Maqbool. Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma. Hematology/Oncology and Stem Cell Therapy 2020; 13(3): 168 doi: 10.1016/j.hemonc.2018.03.004
|
| 5 |
Scott C. Howard, Ching-Hon Pui, Raul C. Ribeiro. Renal Disease in Cancer Patients. 2014; : 39 doi: 10.1016/B978-0-12-415948-8.00004-0
|
| 6 |
Roshan Agarwala, Akash Batta, Varun Suryadevera, Vivek Kumar, Vishal Sharma, Surinder Singh Rana. Spontaneous tumour lysis syndrome in hepatocellular carcinoma presenting with hypocalcemic tetany: An unusual case and systematic literature review. Clinics and Research in Hepatology and Gastroenterology 2017; 41(3): e29 doi: 10.1016/j.clinre.2016.09.003
|
| 7 |
Ho Hung Cheung, Wong Hoi She, Desmond Y.H. Yap, Simon H.Y. Tsang, Tan To Cheung. A case report of tumor lysis syndrome after stage-one ALPPS. Medicine 2022; 101(10): e29040 doi: 10.1097/MD.0000000000029040
|
| 8 |
P. Bose, O. Qubaiah. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. Journal of Clinical Pharmacy and Therapeutics 2011; 36(3): 299 doi: 10.1111/j.1365-2710.2011.01260.x
|
| 9 |
Yuhi Sakamoto, Keizo Kato, Hiroshi Abe, Takeshi Yonezawa, Sadahiro Ito, Makiko Ika, Kiichiro Yoza, Mamika Ohara, Shogo Sakasai, Shohei Shimizu, Shinji Endo. A case of hepatocellular carcinoma caused severe tumor lysis by ramucirumab. Kanzo 2021; 62(3): 129 doi: 10.2957/kanzo.62.129
|
| 10 |
Franziska Schmidt, Miriam Erlacher, Charlotte Niemeyer, Dirk Reinhardt, Jan-Henning Klusmann. Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML. Frontiers in Pediatrics 2022; 10 doi: 10.3389/fped.2022.1046586
|
| 11 |
Jen-Wei Chou, Ken-Sheng Cheng, Trupti Akella, Chi Chan Lee, Teressa Ju. Tumor Lysis Syndrome in Patients With Hepatocellular Carcinoma: A Systematic Review of Published Case Reports
. Cureus 2021; doi: 10.7759/cureus.19128
|
| 12 |
Khurram Abbass, Shabana Dewani, Ronald Markert, Michael K Kaplon, Michael A Baumann. All That Glitters: Sorafenib. Internal Medicine 2011; 50(7): 797 doi: 10.2169/internalmedicine.50.4858
|
| 13 |
Matthew R. Kearney, Emerson Y. Chen, Peter Stenzel, Christopher L. Corless, Thomas G. Deloughery, Mark Zivney, Charles D. Lopez. Colorectal Cancer-Associated Spontaneous Tumor Lysis Syndrome: a Case Report and Review of the Current Literature. Journal of Gastrointestinal Cancer 2019; 50(3): 668 doi: 10.1007/s12029-018-0102-7
|
| 14 |
Belal M. Firwana, Rim Hasan, Nour Hasan, Fares Alahdab, Iyad Alnahhas, Seba Hasan, Joseph Varon. Tumor Lysis Syndrome: A Systematic Review of Case Series and Case Reports. Postgraduate Medicine 2012; 124(2): 92 doi: 10.3810/pgm.2012.03.2540
|
| 15 |
Naoki Yamashita, Aritsune Ooho, Akihiro Yamasaki, Miho Kurokawa, Mitsuru Kinjo, Eiji Kajiwara. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma. Kanzo 2014; 55(4): 228 doi: 10.2957/kanzo.55.228
|
| 16 |
Bilal Farooqi, Josh Simmons, Zhonglin Hao. Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib. Journal of Gastrointestinal Cancer 2015; 46(3): 314 doi: 10.1007/s12029-015-9711-6
|
| 17 |
DEITER J. DUFF, SHADI HADDADIN, CARL FRETER, CHRIS PAPAGEORGIOU. Gemcitabine and cisplatin-induced tumor lysis syndrome in a patient with gallbladder carcinoma: A case report. Oncology Letters 2013; 5(4): 1237 doi: 10.3892/ol.2013.1189
|
| 18 |
Krishna Sury. Update on the prevention and treatment of tumor lysis syndrome. Journal of Onco-Nephrology 2019; 3(1): 19 doi: 10.1177/2399369319837212
|
| 19 |
Raman Mehrzad, Hiroki Saito, Zachary Krahn, Alexander Feinstein. Spontaneous Tumor Lysis Syndrome in a Patient with Metastatic Hepatocellular Carcinoma. Medical Principles and Practice 2014; 23(6): 574 doi: 10.1159/000360362
|
| 20 |
Kensuke Yamamura, Toru Beppu, Nobutaka Sato, Eri Oda, Koichi Kinoshita, Hideaki Yuki, Toshihiko Motohara, Hideaki Miyamoto, Tsutomu Oda, Shinichi Akahoshi. Huge hepatocellular carcinoma with extrahepatic collateral arteries successfully treated by multidisciplinary treatment including laparoscopic devascularization: a case report. Clinical Journal of Gastroenterology 2021; 14(1): 251 doi: 10.1007/s12328-020-01286-2
|
| 21 |
Jin Ok Kim, Dae Won Jun, Hye Jin Tae, Kang Nyeong Lee, Hang Lak Lee, Oh Young Lee, Ho Soon Choi, Byung Chul Yoon, Joon Soo Hahm. Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient. Clinical and Molecular Hepatology 2015; 21(1): 85 doi: 10.3350/cmh.2015.21.1.85
|
| 22 |
Katsutoshi Sugimoto, Fuminori Moriyasu, Kazuhiro Saito, Nicolas Rognin, Naohisa Kamiyama, Yoshihiro Furuichi, Yasuharu Imai. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US. Liver International 2013; 33(4): 605 doi: 10.1111/liv.12098
|
| 23 |
Mitsuhiro Furusawa, Kozue Matsuishi, Kei Horino, Hideki Inoue, Michio Abe, Natsuo Oya. A Case of Tumor Lysis Syndrome during Palliative Radiotherapy for Breast Cancer Metastases. Case Reports in Oncology 2023; 16(1): 1060 doi: 10.1159/000531925
|
| 24 |
Robert E. Lynch, Ellen G. Wood. Pediatric Critical Care. 2011; : 944 doi: 10.1016/B978-0-323-07307-3.10067-9
|
| 25 |
Shin Young Kim, Hee Yeon Kim, Yu Seung Kim, Sang Min Lee, Chang Wook Kim. Tumor lysis syndrome following sorafenib treatment in hepatocellular carcinoma. Yeungnam University Journal of Medicine 2015; 32(1): 47 doi: 10.12701/yujm.2015.32.1.47
|
| 26 |
Karen P. Seiter, Nicholas J. Sarlis, Edward S. Kim. Management of hyperuricemia in adults with or at risk of tumor lysis syndrome. Community Oncology 2011; 8(4): 163 doi: 10.1016/S1548-5315(12)70067-0
|
| 27 |
Gareth P. Gregory, Jake Shortt. Textbook of Palliative Care. 2018; : 1 doi: 10.1007/978-3-319-31738-0_76-1
|
| 28 |
Riyadh M Alqurashi , Husam H Tamim, Ziyad D Alsubhi, Alyazid A Alzahrani, Emad Tashkandi. Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases. Cureus 2022; doi: 10.7759/cureus.30652
|
| 29 |
Gareth P. Gregory, Jake Shortt. Textbook of Palliative Care. 2019; : 1421 doi: 10.1007/978-3-319-77740-5_76
|
| 30 |
Katsutoshi Sugimoto, Kazuhiro Saito, Mitsuyoshi Honjo, Yuki Miyata, Takatomo Sano, Shigeki Ichimura, Eigaku Murashima, Junichi Taira, Kota Yamada, Yoshihiro Furuichi, Masahiko Yamada, Yasuharu Imai, Ikuo Nakamura, Fuminori Moriyasu. A case of advanced hepatocellular carcinoma who died of metabolic encephalopathy early in the course of treatment with sorafenib with marked changes in imaging findings. Kanzo 2010; 51(5): 227 doi: 10.2957/kanzo.51.227
|
| 31 |
Scott C. Howard, Deborah P. Jones, Ching-Hon Pui. The Tumor Lysis Syndrome. New England Journal of Medicine 2011; 364(19): 1844 doi: 10.1056/NEJMra0904569
|
| 32 |
Jia Yuan, Hongming Liang, Jinghuan Li, Miao Li, Bei Tang, Hui Ma, Xiaoying Xie, Xin Yin, Lan Zhang, Zhenggang Ren. Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib. Molecular and Clinical Oncology 2017; 7(5): 837 doi: 10.3892/mco.2017.1416
|
| 33 |
Aibek E. Mirrakhimov, Alaa M. Ali, Maliha Khan, Aram Barbaryan. Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature. Rare Tumors 2014; 6(2): 68 doi: 10.4081/rt.2014.5389
|
| 34 |
Yoshiaki Shimizu, Hajime Sunagozaka, Koki Yamagata, Hirokazu Hirai, Miyabi Miura, Yuichiro Yonemoto, Yoshihide Naito, Kenkei Hasatani, Jun Yoshikawa, Hiroyuki Aoyagi, Shuichi Kaneko. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report. Clinical Journal of Gastroenterology 2021; 14(2): 645 doi: 10.1007/s12328-020-01306-1
|
| 35 |
Danica Maria Vodopivec, Jose Enrique Rubio, Alessia Fornoni, Oliver Lenz. An Unusual Presentation of Tumor Lysis Syndrome in a Patient with Advanced Gastric Adenocarcinoma: Case Report and Literature Review. Case Reports in Medicine 2012; 2012: 1 doi: 10.1155/2012/468452
|
| 36 |
Benjamin Rahmani, Shrey Patel, Omar Seyam, Jason Gandhi, Inefta Reid, Noel Smith, Sardar Ali Khan. Current understanding of tumor lysis syndrome. Hematological Oncology 2019; 37(5): 537 doi: 10.1002/hon.2668
|